Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Tori Fuller"'
Autor:
Caroline Diorio, Tiffaney L. Vincent, Tori Fuller, Rawan Shraim, Tina Glisovic-Aplenc, Theresa Ryan, Kimberly Veliz, Haley Newman, Gerald Wertheim, Hamid Bassiri, Annette Vu, Michael Hogarty, Carl H June, Stephan A. Grupp, Sarah K Tasian, Richard Aplenc, Saar Gill, David T. Teachey
Publikováno v:
Blood. 140:10285-10286
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c3794ffa9bedf94a417b70cd6137cbf
https://doi.org/10.1182/blood-2022-167893
https://doi.org/10.1182/blood-2022-167893
Autor:
Caroline Diorio, Ryan Murray, Mark Naniong, Luis Barrera, Adam Camblin, John Chukinas, Lindsey Coholan, Aaron Edwards, Tori Fuller, Claudia Gonzales, Stephan A. Grupp, Alden Ladd, Melissa Le, Angelica Messana, Faith Musenge, Haley Newman, Yeh-Chuin Poh, Henry Poulin, Theresa Ryan, Rawan Shraim, Sarah K. Tasian, Tiffaney Vincent, Lauren Young, Yingying Zhang, Giuseppe Ciaramella, Jason Gehrke, David T. Teachey
Publikováno v:
Blood. 140(6)
Allogeneic chimeric antigen receptor T-cell (CART) therapies require multiple gene edits to be clinically tractable. Most allogeneic CARTs have been created using gene editing techniques that induce DNA double-stranded breaks (DSBs), resulting in uni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba2ae70e7c54066b4db124ac12ee2801
https://pubmed.ncbi.nlm.nih.gov/35951345
https://pubmed.ncbi.nlm.nih.gov/35951345
Autor:
Richard Aplenc, Tori Fuller, Brent L. Wood, Soo Yeon Im, Stuart S. Winter, Robin Carson, David T. Teachey, Tiffaney Vincent, Stephen P. Hunger, Stephan A. Grupp, Tina Glisovic-Aplenc, Kimberly P. Dunsmore, William L. Carroll, Mignon L. Loh, Terzah M. Horton, Michelle L. Hermiston, Elizabeth A. Raetz, Yunfeng Dai, Shannon L. Maude, Karen L. Bride, Meenakshi Devidas, David M. Barrett
Publikováno v:
Blood. 131(9)
As a consequence of acquired or intrinsic disease resistance, the prognosis for patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) is dismal. Novel, less toxic drugs are clearly needed. One of the most promising emerging
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b36bff59a4a5a04844b892e17672172f
https://pubmed.ncbi.nlm.nih.gov/29496700
https://pubmed.ncbi.nlm.nih.gov/29496700
Autor:
Karen L. Bride, Mignon L. Loh, David M. Barrett, Theresa Ryan, Brent L. Wood, Shannon L. Maude, Tiffaney Vincent, Michelle L. Hermiston, David T. Teachey, Stephan A. Grupp, Soo-Yeon L. Im, Tori Fuller
Publikováno v:
Cancer Research. 77:2642-2642
Targeted immunotherapy has become critical for the successful treatment of many forms of cancer, particularly therapeutic antibodies with cytotoxic abilities. No safe and effective immunotherapies have been developed for T-cell acute lymphoblastic le
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ba8a8b8651bcd3d747d36c0c8b98f78
https://doi.org/10.1158/1538-7445.am2017-2642
https://doi.org/10.1158/1538-7445.am2017-2642